RxDoctor Payments Data

Cherie Lamb, DO

Hospitalist · Atlanta, GANPI 1952573768

Payments from drug & device makers

$1,339in general payments, 2019–2025

Across 62 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$425
  • AstraZeneca$138
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$114
  • Pfizer$102
  • Smith+Nephew$74
  • Boehringer Ingelheim$74
  • plus $412 from 12 others

What the payments were for

  • Food & beverage$1,339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,339 in reported general payments places this provider in the 85th percentile of 812 hospitalist providers in Georgia.

See all hospitalist providers in Georgia

Medicare billing

Part B allowed, 2024
$83,544
Medicare patients
307
Services billed
731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$10,670
Mirtazapine28$709
Rivastigmine12$652
Hydralazine Hcl42$592
Atorvastatin Calcium35$405
Pantoprazole Sodium63$269
Albuterol Sulfate HfaAlbuterol Sulfate11$234
Ondansetron OdtOndansetron19$178
Carvedilol27$152
Gabapentin16$138
Amlodipine Besylate44$110
Oxycodone Hcl25$108
ClopidogrelClopidogrel Bisulfate14$106
Trazodone Hcl14$103
Tamsulosin Hcl11$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$10,67018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 812 hospitalist providers in Georgia.

Other hospitalist in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →